Combined Induction Therapy with Rabbit Antithymocyte Globulin and Rituximab in Highly Sensitized Renal Recipients

References

• Adams AB, Newell KA. (2012). B cells in clinical transplantation tolerance. Semin Immunol, 24, 92–5
   PubMed Web of Science ®Google Scholar
• Barama A, Oza U, Panek R, et al. (2000). Effect of recipient sensitization (peak PRA) on graft outcome in haploidentical living related kidney transplants. Clin Transplant, 14, 212–17
   PubMed Web of Science ®Google Scholar
• Basu A, Falcone J, Dvorchik I, et al. (2011). Outcomes of renal transplantation in recipients with peak panel reactive antibody >30% under tacrolimus-based immunosuppression. Ann Transplant, 16, 5–13
   PubMed Web of Science ®Google Scholar
• Becker YT, Becker BN, Pirsch JD, Sollinger HW. (2004). Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant, 4, 996–1001
   PubMed Web of Science ®Google Scholar
• Becker YT, Samaniego-Picota M, Sollinger HW. (2006). The emerging role of rituximab in organ transplantation. Transpl Int, 19, 621–8
   PubMed Web of Science ®Google Scholar
• Bouaziz JD, Calbo S, Maho-Vaillant M, et al. (2010). IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro. Eur J Immunol, 40, 2686–91
   PubMed Web of Science ®Google Scholar
• Cai J, Terasaki PI. (2010). The current trend of induction and maintenance treatment in patient of different PRA levels: A report on OPTN/UNOS Kidney Transplant Registry data. Clin Transplant, 2010, 45–52
   Google Scholar
• Clatworthy MR, Watson CJ, Plotnek G, et al. (2009). B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med, 360, 2683–5
   PubMed Web of Science ®Google Scholar
• Cooper JE, Gralla J, Cagle L, et al. (2011). Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation, 91, 1103–9
   PubMed Web of Science ®Google Scholar
• de Wit J, Souwer Y, Jorritsma T, et al. (2010). Antigen-specific B cells reactivate an effective cytotoxic T cell response against phagocytosed Salmonella through cross-presentation. PLoS One, 5, e13016
   PubMed Web of Science ®Google Scholar
• Domingues EM, Matuck T, Graciano ML, et al. (2010). Panel reactive HLA antibodies, soluble CD30 levels, and acute rejection six months following renal transplant. Clin Transplant, 24, 821–9
   PubMed Web of Science ®Google Scholar
• Donaldson PT, Williams R. (1997). Cross-matching in liver transplantation. Transplantation, 63, 789–94
   PubMed Web of Science ®Google Scholar
• Einecke G, Sis B, Reeve J, et al. (2009). Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant, 9, 2520–31
   PubMed Web of Science ®Google Scholar
• Faguer S, Kamar N, Guilbeaud-Frugier C, et al. (2007). Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation, 83, 1277–80
   PubMed Web of Science ®Google Scholar
• Gartner V, Eigentler TK, Viebahn R. (2006). Plasma cell-rich rejection processes in renal transplantation: Morphology and prognostic relevance. Transplantation, 81, 986–91
   PubMed Web of Science ®Google Scholar
• Gloor JM, Winters JL, Cornell LD, et al. (2010). Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant, 10, 582–9
   PubMed Web of Science ®Google Scholar
• Heidt S, Hester J, Shankar S, et al. (2012). B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naive B cells. Am J Transplant, 12, 1784–92
   PubMed Web of Science ®Google Scholar
• Hippen BE, DeMattos A, Cook WJ, et al. (2005). Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. Am J Transplant, 5, 2248–52
   PubMed Web of Science ®Google Scholar
• Hoshino J, Kaneku H, Everly MJ, et al. (2012). Using donor-specific antibodies to monitor the need for immunosuppression. Transplantation, 93, 1173–8
   PubMed Web of Science ®Google Scholar
• Kelishadi SS, Azimzadeh AM, Zhang T, et al. (2010). Preemptive CD20+ B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeys. J Clin Invest, 120, 1275–84
   PubMed Web of Science ®Google Scholar
• Kopchaliiska D, Zachary AA, Montgomery RA, Leffell MS. (2009). Reconstitution of peripheral allospecific CD19+ B-cell subsets after B-lymphocyte depletion therapy in renal transplant patients. Transplantation, 87, 1394–401
   PubMed Web of Science ®Google Scholar
• Kozlowski T, Andreoni K. (2011). Limitations of rituximab/IVIg desensitization protocol in kidney transplantation; is this better than a tincture of time? Ann Transplant, 16, 19–25
   PubMed Web of Science ®Google Scholar
• Lefaucheur C, Nochy D, Hill GS, et al. (2007). Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant, 7, 832–41
   PubMed Web of Science ®Google Scholar
• Lefaucheur C, Suberbielle-Boissel C, Hill GS, et al. (2008). Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant, 8, 324–31
   PubMed Web of Science ®Google Scholar
• Liu C, Noorchashm H, Sutter JA, et al. (2007). B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat Med, 13, 1295–8
   PubMed Web of Science ®Google Scholar
• Loupy A, Suberbielle-Boissel C, Zuber J, et al. (2010). Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: A pilot study. Transplantation, 89, 1403–10
   PubMed Web of Science ®Google Scholar
• Marfo K, Ling M, Bao Y, et al. (2012). Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients. Transplantation, 94, 345–51
   PubMed Web of Science ®Google Scholar
• Matas AJ, Smith JM, Skeans MA, et al. (2014). OPTN/SRTR 2012 annual data report: Kidney. Am J Transplant, 14, 11–44
   PubMed Web of Science ®Google Scholar
• Michaels PJ, Kobashigawa J, Laks H, et al. (2001). Differential expression of RANTES chemokine, TGF-beta, and leukocyte phenotype in acute cellular rejection and quilty B lesions. J Heart Lung Transplant, 20, 407–16
   PubMed Web of Science ®Google Scholar
• Mullins P, Solis E, Prat A, et al. (1989). Cardiac and lung transplantation. Curr Opin Immunol, 2, 837–41
   PubMed Web of Science ®Google Scholar
• Munoz AS, Rioveros AA, Cabanayan-Casasola CB, et al. (2008). Rituximab in highly sensitized kidney transplant recipients. Transplant Proc, 40, 2218–21
   PubMed Web of Science ®Google Scholar
• Nickeleit V, Andreoni K. (2007). The classification and treatment of antibody-mediated renal allograft injury: Where do we stand? Kidney Int, 71, 7–11
   PubMed Web of Science ®Google Scholar
• Pankewycz O, Leca N, Kohli R, et al. (2011). Low-dose rabbit antithymocyte globulin induction therapy results in prolonged selective lymphocyte depletion irrespective of maintenance immunosuppression. Transplant Proc, 43, 462–5
   PubMed Web of Science ®Google Scholar
• Paramesh AS, Zhang R, Baber J, et al. (2010). The effect of HLA mismatch on highly sensitized renal allograft recipients. Clin Transplant, 24, E247–52
   PubMed Web of Science ®Google Scholar
• Parsons RF, Redfield RR III, Rodriguez E, et al. (2012). Primary B cell repertoire remodeling to achieve humoral transplantation tolerance. Semin Immunol, 24, 109–14
   PubMed Web of Science ®Google Scholar
• Rhee J, Al-Mana N, Freeman R. (2009). Immunosuppression in high-risk transplantation. Curr Opin Organ Transplant, 14, 636–42
   PubMed Web of Science ®Google Scholar
• Smith JD, Danskine AJ, Laylor RM, et al. (1993). The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heart and heart-lung transplantation. Transpl Immunol, 1, 60–5
   PubMedGoogle Scholar
• Stroopinsky D, Katz T, Rowe JM, et al. (2012). Rituximab-induced direct inhibition of T-cell activation. Cancer Immunol Immunother, 61, 1233–41
   PubMed Web of Science ®Google Scholar
• Takagi T, Ishida H, Shirakawa H, et al. (2010a). Changes in anti-HLA antibody titers more than 1 year after desensitization therapy with rituximab in living-donor kidney transplantation. Transplant Immunol, 23, 220–3
   PubMed Web of Science ®Google Scholar
• Takagi T, Ishida H., Shirakawa H, et al. (2010b). Evaluation of low-dose rituximab induction therapy in living related kidney transplantation. Transplantation, 89, 1466–70
   PubMed Web of Science ®Google Scholar
• Tchao NK, Turka LA. (2012). Lymphodepletion and homeostatic proliferation: Implications for transplantation. Am J Transplant, 12, 1079–90
   PubMed Web of Science ®Google Scholar
• Terasaki PI, Cai J. (2005). Humoral theory of transplantation: Further evidence. Curr Opin Immunol, 17, 541–5
   PubMed Web of Science ®Google Scholar
• Thaunat O. (2011). Pathophysiologic significance of B-cell clusters in chronically rejected grafts. Transplantation, 92, 121–6
   PubMed Web of Science ®Google Scholar
• Tsai EW, Rianthavorn P, Gjertson DW, et al. (2006). CD20+ lymphocytes in renal allografts are associated with poor graft survival in pediatric patients. Transplantation, 82, 1769–73
   PubMed Web of Science ®Google Scholar
• Tyden G, Kumlien G, Genberg H, et al. (2005). ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant, 5, 145–8
   PubMed Web of Science ®Google Scholar
• Vo AA, Peng A, Toyoda M, et al. (2010). Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation, 89, 1095–102
   PubMed Web of Science ®Google Scholar
• Wehner J, Morrell CN, Reynolds T, et al. (2007). Antibody and complement in transplant vasculopathy. Circ Res, 100, 191–203
   PubMed Web of Science ®Google Scholar
• Wiebe C, Gibson IW, Blydt-Hansen TD, et al. (2012). Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant, 12, 1157–67
   PubMed Web of Science ®Google Scholar
• Yin H, Wan H, Hu XP, et al. (2011). Rituximab induction therapy in highly sensitized kidney transplant recipients. Chin Med J, 124, 1928–32
   PubMed Web of Science ®Google Scholar
• Zaltzman JS, Boucher A, Busque S, et al. (2005). A prospective 3-yr evaluation of tacrolimus-based immunosuppressive therapy in immunological high risk renal allograft recipients. Clin Transplant, 19, 26–32
   PubMed Web of Science ®Google Scholar
• Zarkhin V, Li L, Kambham N, et al. (2008). A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant, 8, 2607–17
   PubMed Web of Science ®Google Scholar